Lonza Group Ltd (LZAGY)
62.99
+1.32
(+2.14%)
USD |
OTCM |
Nov 01, 16:00
Lonza Group Debt to Equity Ratio: 0.4058 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.4058 |
| December 31, 2023 | 0.2963 |
| June 30, 2023 | 0.2824 |
| December 31, 2022 | 0.2106 |
| June 30, 2022 | 0.24 |
| December 31, 2021 | 0.2465 |
| June 30, 2021 | 0.5019 |
| December 31, 2020 | 0.5253 |
| June 30, 2020 | 0.5896 |
| December 31, 2019 | 0.5451 |
| June 30, 2019 | 0.6129 |
| December 31, 2018 | 0.6515 |
| June 30, 2018 | 0.6637 |
| December 31, 2017 | 0.6904 |
| June 30, 2017 | 0.3231 |
| December 31, 2016 | 0.808 |
| Date | Value |
|---|---|
| June 30, 2016 | 0.8592 |
| December 31, 2015 | 0.9054 |
| June 30, 2015 | 1.055 |
| December 31, 2014 | 1.040 |
| June 30, 2014 | 1.184 |
| December 31, 2013 | 1.165 |
| June 30, 2013 | 1.300 |
| December 31, 2012 | 1.339 |
| June 30, 2012 | 1.227 |
| December 31, 2011 | 1.357 |
| June 30, 2011 | 0.65 |
| December 31, 2010 | 0.6116 |
| June 30, 2010 | 0.5944 |
| December 31, 2009 | 0.6426 |
| June 30, 2009 | 0.00 |
| December 31, 2008 | 1.251 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.2106
Minimum
Dec 2022
0.5896
Maximum
Jun 2020
0.3844
Average
0.351
Median
Debt to Equity Ratio Benchmarks
| AC Immune SA | 0.00 |
| CRISPR Therapeutics AG | -- |
| Addex Therapeutics Ltd | 0.00 |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 19.89B |
| Total Liabilities (Quarterly) | 9.422B |
| Shareholders Equity (Quarterly) | 10.40B |
| Current Ratio | 2.042 |
| Net Debt Paydown Yield | -1.54% |